Drug Profile
CHF 6297
Alternative Names: CHF-6297; CHI-91040; MAPK14 inhibitorLatest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator Pulmagen Therapeutics
- Developer Chiesi Farmaceutici
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Chronic obstructive pulmonary disease
- No development reported Asthma
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for preclinical development in Asthma in Italy (Inhalation)
- 21 Oct 2020 CHF 6297 is still in phase I/II trials for Chronic obstructive pulmonary disease in United Kingdom (Chiesi Farmaceutici pipeline, October 2020)
- 02 May 2019 Chiesi Farmaceutici terminates the phase I/II CHF6297 FIH trial in Chronic obstructive pulmonary disease in United Kingdom due to very poor recruitment in the Part 4 of the study (Inhalation) (NCT02815488)